NDA 019221 · Bausch
Vaseretic
Enalapril Maleate, Hydrochlorothiazide · Oral · Thiazide Diuretic
Last checked: Nov 19, 2026Latest source record: Aug 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Oct 31, 1986
Approved uses
2
Original approval plus efficacy supplements
Registered trials
156
43 Phase 3, 13 recruiting
FAERS reports
912
787 serious, 61 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. • When pregnancy is detected, discontinue VASERETIC ® as soon as possible. • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS: Fetal Toxicity
What it is approved for
From the label in effect Aug 31, 2020.
INDICATIONS AND USAGE VASERETIC is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial treatment (see DOSAGE AND ADMINISTRATION ). In using VASERETIC, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see WARNINGS ). In considering use of VASERETIC, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema ).
Mechanism: Mechanism of Action Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Although the latter decrease is small, it results in small increases of serum potassium. In hypertensive...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 12, 1995 Supplement 15 · Efficacy
- Oct 31, 1986 Original approval · Type 4 - New Combination
2 products under this application
- VASERETIC · ENALAPRIL MALEATE 5MG; HYDROCHLOROTHIAZIDE 12.5MG · TABLET, ORAL · Prescription · TE AB
- VASERETIC · ENALAPRIL MALEATE 10MG; HYDROCHLOROTHIAZIDE 25MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Enalapril" as an intervention, any sponsor and status, largest first.
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- China Stroke Primary Prevention TrialPivotal-lookingCompleted
Shenzhen Ausa Pharmed Co.,LtdIndustry
NCT00794885 · 20,702 participants · Start May 2008 · Primary completion Aug 2013
Drug: Enalapril/folic acid; Enalapril maleate · For: Primary Hypertension
Sites: Anqing, China; Lianyungang, China
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive SubjectsPivotal-lookingStatus unknown
Ramathibodi HospitalAcademic, hospital or other
NCT01364675 · 8,900 participants (planned) · Start Jan 2012 · Primary completion Jul 2016
Drug: Metformin+Enalapril+Simvastatin; Placebo tablet · For: Pre-diabetes; Pre-hypertension
Sites: Muang District, Thailand
- This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart FailurePivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT01035255 · 8,442 participants · Start Dec 2009 · Primary completion May 2014
Drug: LCZ696 200 mg BID; Enalapril 10 mg BID · For: Heart Failure With Reduced Ejection Fraction
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 1,031 sites in all
- Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPillPivotal-lookingCompleted
Tehran University of Medical SciencesAcademic, hospital or other
NCT01271985 · 8,410 participants · Start Feb 2011 · Primary completion Jan 2019
Drug: PolyPill · For: Cardiovascular Diseases
Sites: Gonbad, Iran
- Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart FailurePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00853658 · 7,064 participants · Start Mar 2009 · Primary completion Oct 2015
Drug: Enalapril; Aliskiren · For: Chronic Heart Failure
Sites: Huntsville, Alabama; Mobile, Alabama; Tucson, Arizona · 806 sites in all
- Systolic Hypertension in Europe Placebo-Controlled TrialPivotal-lookingTerminated
KU LeuvenAcademic, hospital or other
NCT02088450 · 4,695 participants · Start Feb 1990 · Primary completion Feb 1997
Drug: Active treatment with nitrendipine (10-40 mg/day). · For: Isolated Systolic Hypertension
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug interaction58
- diarrhoea54
- nausea48
- fall45
- renal failure acute44
- dizziness38
- vomiting36
- hypotension35
- hyponatraemia34
- renal failure34
- dyspnoea32
- drug ineffective31
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 73 |
| 2005 | 79 |
| 2006 | 67 |
| 2007 | 42 |
| 2008 | 73 |
| 2009 | 72 |
| 2010 | 85 |
| 2011 | 120 |
| 2012 | 90 |
| 2013 | 11 |
| 2014 | 22 |
| 2015 | 17 |
| 2016 | 19 |
| 2017 | 13 |
| 2018 | 36 |
| 2019 | 24 |
| 2020 | 31 |
| 2021 | 13 |
| 2022 | 5 |
| 2023 | 9 |
| 2024 | 4 |
| 2025 | 6 |
| 2026 | 1 |
Recalls
1 FDA enforcement reports for this application.
May 21, 2014 · Class III · Terminated
Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package outset
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vaseretic (Enalapril/Hydrochlorothiazide)
2024 spending
$76K
Beneficiaries
47
111 claims
Per beneficiary
$1,628
$11.08 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $234,107 |
| 2021 | $177,429 |
| 2022 | $139,691 |
| 2023 | $80,586 |
| 2024 | $76,499 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ, Packer M, Desai AS, et al. · N Engl J Med 2014 · Comparative Study, Multicenter Study
- Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ, Morrow DA, DeVore AD, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
· N Engl J Med 1987 · Clinical Trial, Randomized Controlled Trial
- Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial.
Huo Y, Li J, Qin X, et al. · JAMA 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Renal protective effect of enalapril in diabetic nephropathy.
Björck S, Mulec H, Johnsen SA, et al. · BMJ 1992 · Clinical Trial, Randomized Controlled Trial
- Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
Yusuf S, Pitt B, Davis CE, et al. · N Engl J Med 1991 · Clinical Trial, Multicenter Study
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.